SEC Form 4 · accession 0001193125-26-266433
Axsome Therapeutics, Inc. · AXSM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Coleman
Director
Period of report
Jun 8, 2026
Accepted (ET)
Jun 10, 2026 · 9:49 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001579428
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F1 | Jun 8, 2026 | M | 1,429 | — | A | 31,032 | D | |
| Common StockF4,F5 | Jun 10, 2026 | S | 643 | $249.00 | D | 30,389 | D | |
| Common StockF6 | holding | — | — | — | 403,856 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1 | — | Jun 8, 2026 | M | 1,429 | D | — | — | Common Stock | 1,429 | 0 | D |
Explanation of responses
- F1Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- F2On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant.
- F3Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.
- F4These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025.
- F5Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $245.17 and $253.04.
- F6Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.